Merck & Company (MRK)

$148.35 -1.19 (-0.80%)
Market Cap 366.00B
Revenue (ttm) 65.01B
Net Income (ttm) 18.25B
EPS (ttm) N/A
PE Ratio 46.59
Forward PE 54.12
Profit Margin 28.08%
Debt to Equity Ratio 1.22
Volume 8,067,800
Avg Vol 10,597,598
Day's Range N/A - N/A
Shares Out 2.47B
Stochastic %K 61%
Beta 0.19
Analysts Strong Sell
Price Target $148.30

Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health manageme...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 908 740 4000
Address:
126 East Lincoln Avenue, Rahway, United States
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 31 at 6:02 AM
$SLS $MRK $MRNA $ABBV $SLS is worth $50B to big pharma the instant Gps Phase 3 results are announced - any day now. • Why Did the VIALE-M Phase 3 Trial for AML First Remission Patients Fail? • Why DID ABBV have difficulty ENROLLING PATIENTS in the AML Maintenance Trial? Why are We SEEING MIRACULOUS Survival in the SLS Phase 3 AML Remission Maintenance Trial - when BAT for CONTROL Patients FAILED 2 Phase 3 AML Remission Trials?
0 · Reply
TradeThePool
TradeThePool Aug. 31 at 5:58 AM
Can $MRNA conquer cancer with AI and mRNA? First Phase 3 win for a personalized mRNA cancer vaccine. Intismeran plus $MRK Keytruda beat Keytruda alone on melanoma recurrence and spread. Up to 34 neoantigens per patient. Then a $2.6B zero-coupon convertible, upsized, with hedges to cap dilution. Argus to Buy, $180 target. XFG booster cleared by FDA and MHRA. COVID paid for the factory. Cancer is the bid. $MRNA $MRK #mRNA #Oncology #Biotech #CancerVaccine
0 · Reply
Duncan74
Duncan74 Aug. 31 at 2:46 AM
$BMY $JNJ $MRK $SLS If you think the auction is only about GPS maintenance, you are completely missing the SLS009 CDK9 hammer. The data room isn't just a clinical file cabinet. It’s a structural playground where SLS009 solves every single pipeline crisis Big Pharma is facing. JNJ’s Phase 3 bleximenib faces severe resistance because leukemia cells ramp up MCL-1 survival proteins. SLS009 is engineered specifically to downregulate and destroy MCL-1, giving JNJ the ultimate combination booster BMS’s current AML lines rely on venetoclax, but patients inevitably relapse. SLS009 has fully matured data proving it forces deep, clean remissions in patients who completely failed venetoclax. Merck needs SLS009 to clear out immune-suppressive myeloid barriers, priming the field for a massive Keytruda combination monopoly. Sellas owns a closed-loop rescue canopy. SLS009 forces the remission, and GPS locks the maintenance vault.
0 · Reply
Duncan74
Duncan74 Aug. 31 at 2:39 AM
$SLS $MRK $BMY $JNJ Let the three giants fight it out to see who writes the biggest upfront cash/stock check for a total oncology monopoly. This is a textbook bidding collision. 🔥Look at the corporate battle lines: 1. BMS: Must defensively protect its AML maintenance crown (Onureg) from JNJ's threatening Phase 3 cAMeLot-2 trials. Buying Sellas blocks JNJ and secures their monopoly. 2. JNJ: Slashed early R&D by 42%. Their lead asset bleximenib is stuck in a narrow 15% mutation niche. They must buy Sellas’s universal WT1 platform to capture the other 85% of AML patients. 3. Merck: Pipelines are dangerously top-heavy after Phase 1 starts tripled. Facing a massive patent cliff, they desperately need advanced Phase 3 anchors like GPS to pair with Keytruda and extend their oncology dominance. 🧬🚀
0 · Reply
TNNStockAnalysisNews
TNNStockAnalysisNews Aug. 31 at 1:36 AM
Stock Catalysts for September 2026: $KDK — Lockup Expiration: September 25 $XRPN — Shareholder Vote: September 30 $RKLB — Neutron Rocket Milestone Watch $BFRI — PDUFA Date: September 28 $MRK — PDUFA Date: September 21 https://truthsandnews.com/markets/stock-catalysts-september-2026-names-to-watch-now
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 30 at 9:12 PM
$SLS $MRK $MRNA $ABBV Gps Immunotherapy has proven Effective in preventing relapse and extending survival IN EVERY PREVIOUS TRIAL -- Including 2 Phase 2 Trials for AML Remission Maintenance. *Phase 3 Trial Results Imminent. Oral Aza -Onureg is the SOC for AML Patients in First Remission - achieved a MOS of 24.7 Months. $ABBV Conducted the VIALE-M PH3 trial Combining Oral Az w Venetoclax - it FAILED. GPS MOS in this Same First Remission Setting Achieved PH2 MOS >67.6 Months. SOC: 24.7 --- GPs: > 67.6 Again Note the Key Gps Specific Immune Response. Onureg Ph3 and GPS P2 Patients were not Eligible for Transplant. 6.7% of the Onureg CR1 Patients Subsequently rec'd transplant.
0 · Reply
Mike22332233
Mike22332233 Aug. 30 at 3:29 PM
$SLS 👉 HERE IS WHAT YOU MUST DO RIGHT NOW WITH SLS ... With proper DD, the outcome here has been clear since the last couple of weeks in December ... The easiest stock to hold is one in which, after doing all your DD, you DO NOT HAVE TO DO ANYMORE THINKING .... just sit back, hold all your shares, and wait !!! I STAND BY ALL MY FOLLOWING RESEARCH ... My current calculation of HR is: 0.25-0.30 * Best asymmetrical play in my 43 yrs investing * At 80th -- 46 GPS/0 BAT Live * GROUNDBREAKING HR * New SoC in AML * GPS in 20 other cancers next * SLS009 only safe CDK9 inhibitor * Minimum BO Offer = $160 * Final Bidding War BO = $222 * Buyer will be $MRK or RHHBY Many don't understand all the positives for the LONGER it takes to get to 80th ... * Patients live longer * HR Value gets lower * BO Valuation gets higher * More will get LT Cap Gains LIKE IF U AGREE ... FOLLOW me 👉 @Mike22332233 to get all SLS info
0 · Reply
NewbieJR
NewbieJR Aug. 30 at 1:16 PM
$MRK
0 · Reply
NewbieJR
NewbieJR Aug. 30 at 9:43 AM
$MRK
0 · Reply
NewbieJR
NewbieJR Aug. 30 at 9:38 AM
$MRK
0 · Reply
Latest News on MRK
Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough

Aug 28, 2026, 6:02 AM EDT - 2 days ago

Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough

MRNA

Explainer: How the Merck/Moderna cancer vaccine works and possible barriers to wide use

Aug 25, 2026, 12:32 PM EDT - 5 days ago

Explainer: How the Merck/Moderna cancer vaccine works and possible barriers to wide use

MRNA

What Happens if Moderna's Cancer Vaccine Works

Aug 25, 2026, 10:37 AM EDT - 5 days ago

What Happens if Moderna's Cancer Vaccine Works

MRNA

Merck price target raised to $170 from $145 at Argus

2026-08-25T12:10:29.000Z - 5 days ago

Merck price target raised to $170 from $145 at Argus

Merck price target raised to $180 from $155 at Wolfe Research

2026-08-25T09:55:17.000Z - 5 days ago

Merck price target raised to $180 from $155 at Wolfe Research

Emily Field: Large pharma companies are going to continue looking at biotech

Aug 24, 2026, 10:45 AM EDT - 6 days ago

Emily Field: Large pharma companies are going to continue looking at biotech

ABBV IBB MRNA XLV

Why Is Merck Stock Still An Undervalued Mega-Cap In Pharma?

Aug 21, 2026, 1:05 PM EDT - 9 days ago

Why Is Merck Stock Still An Undervalued Mega-Cap In Pharma?

Merck price target raised to $160 from $140 at Goldman Sachs

2026-08-21T10:31:19.000Z - 9 days ago

Merck price target raised to $160 from $140 at Goldman Sachs

Merck Stock (MRK) Is a Strong Buy as 3 Top Wall Street Analysts Hike Price Targets

2026-08-20T16:37:43.000Z - 10 days ago

Merck Stock (MRK) Is a Strong Buy as 3 Top Wall Street Analysts Hike Price Targets

BMO GS JEF MS UBS

Moderna is paring back gains, but Merck stock remains a buy

Aug 20, 2026, 11:46 AM EDT - 10 days ago

Moderna is paring back gains, but Merck stock remains a buy

MRNA

Thursday's First Moves: Analysts Mixed on MRNA & MRK Rally, AAP & DE Earnings

Aug 20, 2026, 10:30 AM EDT - 10 days ago

Thursday's First Moves: Analysts Mixed on MRNA & MRK Rally, AAP & DE Earnings

MRNA AAP DE

Moderna Stock Rockets Higher After Positive Cancer Vaccine Trial Data

Aug 20, 2026, 9:26 AM EDT - 10 days ago

Moderna Stock Rockets Higher After Positive Cancer Vaccine Trial Data

MRNA

Merck price target raised to $170 from $142 at BMO Capital

2026-08-20T12:50:38.000Z - 10 days ago

Merck price target raised to $170 from $142 at BMO Capital

Moderna Stock (MRNA) Forecast: BofA Upgrades Rating on Cancer Vaccine Update, Goldman Raises Price Target

2026-08-20T12:30:00.000Z - 10 days ago

Moderna Stock (MRNA) Forecast: BofA Upgrades Rating on Cancer Vaccine Update, Goldman Raises Price Target

MRNA

Merck price target raised to $175 from $145 at UBS

2026-08-20T10:45:16.000Z - 10 days ago

Merck price target raised to $175 from $145 at UBS

Moderna, Merck breakthrough could usher in wave of cancer vaccines

Aug 19, 2026, 4:58 PM EDT - 11 days ago

Moderna, Merck breakthrough could usher in wave of cancer vaccines

MRNA

Merck, Moderna Stocks Soar After Melanoma Trial Success

Aug 19, 2026, 10:28 AM EDT - 11 days ago

Merck, Moderna Stocks Soar After Melanoma Trial Success

MRNA

VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results

Aug 19, 2026, 10:14 AM EDT - 11 days ago

VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results

MRNA

Merck, Moderna Melanoma Vaccine Study Succeeds

Aug 19, 2026, 9:43 AM EDT - 11 days ago

Merck, Moderna Melanoma Vaccine Study Succeeds

MRNA

U.S. Treasury Boosts Debt Buybacks, UAE Cuts Off Iran, MRNA & MRK Melanoma Trial Results

Aug 19, 2026, 9:30 AM EDT - 11 days ago

U.S. Treasury Boosts Debt Buybacks, UAE Cuts Off Iran, MRNA & MRK Melanoma Trial Results

MRNA

'An increased ability to disease-free': Moderna CEO & Merck's Dr. Li on skin cancel vaccine trial

Aug 19, 2026, 8:29 AM EDT - 11 days ago

'An increased ability to disease-free': Moderna CEO & Merck's Dr. Li on skin cancel vaccine trial

MRNA

Moderna, Merck, La-Z-Boy, SK Hynix, and More Stocks That Explain Today's Market

Aug 19, 2026, 7:35 AM EDT - 11 days ago

Moderna, Merck, La-Z-Boy, SK Hynix, and More Stocks That Explain Today's Market

LZB MRNA SKHY

Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial

Aug 19, 2026, 6:48 AM EDT - 11 days ago

Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial

MRNA

Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial

Aug 19, 2026, 6:46 AM EDT - 11 days ago

Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial

MRNA

An experimental mRNA-based cancer vaccine succeeded in preventing melanoma from coming back or spreading in a large study, partners Merck and Moderna said.

Aug 19, 2026, 6:45 AM EDT - 11 days ago

An experimental mRNA-based cancer vaccine succeeded in preventing melanoma from coming back or spreading in a large study, partners Merck and Moderna said.

MRNA

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma

Aug 19, 2026, 6:45 AM EDT - 11 days ago

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma

MRNA

Expert explains why healthcare is a top-performing sector

Aug 13, 2026, 11:15 PM EDT - 17 days ago

Expert explains why healthcare is a top-performing sector

ABBV AMGN BIIB GILD JNJ LLY UNH

Sarah Cannon Research Institute and Merck Collaborate to Expand Access to Oncology Clinical Trials

Aug 13, 2026, 9:00 AM EDT - 17 days ago

Sarah Cannon Research Institute and Merck Collaborate to Expand Access to Oncology Clinical Trials

Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences

Aug 11, 2026, 12:50 PM EDT - 19 days ago

Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences

GSK

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Aug 7, 2026, 1:15 AM EDT - 24 days ago

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

IBB IHE MRNA PJP SMMT XBI

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

Aug 6, 2026, 6:45 AM EDT - 24 days ago

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

Merck & Co. Earnings Call Transcript: Q2 2026

Aug 4, 2026, 9:00 AM EDT - 26 days ago

Merck & Co. Earnings Call Transcript: Q2 2026

Merck & Co. Earnings release: Q2 2026

Aug 4, 2026, 9:00 AM EDT - 26 days ago

Merck & Co. Earnings release: Q2 2026

Merck & Co. Slides: Q2 2026

Aug 4, 2026, 9:00 AM EDT - 26 days ago

Merck & Co. Slides: Q2 2026

Merck & Co. Quarterly report: Q2 2026

Aug 4, 2026, 9:00 AM EDT - 26 days ago

Merck & Co. Quarterly report: Q2 2026

Merck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom Line

Aug 4, 2026, 6:41 AM EDT - 26 days ago

Merck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom Line

Merck posts better-than-expected second-quarter results on Keytruda strength

Aug 4, 2026, 6:35 AM EDT - 26 days ago

Merck posts better-than-expected second-quarter results on Keytruda strength

Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges

Aug 4, 2026, 6:34 AM EDT - 26 days ago

Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges

Merck Delivers a Clean Earnings Beat on Oncology Strength. Is It Enough to Impress Wall Street?

Aug 4, 2026, 6:30 AM EDT - 26 days ago

Merck Delivers a Clean Earnings Beat on Oncology Strength. Is It Enough to Impress Wall Street?

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

Aug 4, 2026, 6:30 AM EDT - 26 days ago

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

Merck & Co. Transcript: Investor update

Aug 3, 2026, 8:00 AM EDT - 27 days ago

Merck & Co. Transcript: Investor update

Merck & Co. Slides: Investor update

Aug 3, 2026, 8:00 AM EDT - 27 days ago

Merck & Co. Slides: Investor update

Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials

Jul 30, 2026, 1:09 AM EDT - 4 weeks ago

Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials

Merck Announces Fourth-Quarter 2026 Dividend

Jul 29, 2026, 11:04 AM EDT - 4 weeks ago

Merck Announces Fourth-Quarter 2026 Dividend

Merck licenses experimental HIV pill to generic makers in 129 countries

Jul 24, 2026, 6:48 AM EDT - 5 weeks ago

Merck licenses experimental HIV pill to generic makers in 129 countries

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

Jul 24, 2026, 6:45 AM EDT - 5 weeks ago

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials

Jul 21, 2026, 1:27 PM EDT - 5 weeks ago

Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials

GILD

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

Jul 21, 2026, 10:00 AM EDT - 5 weeks ago

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

GILD

What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment.

Jul 20, 2026, 2:00 AM EDT - 6 weeks ago

What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment.

Use These ETFs as Health Stocks LLY, UNH, MRK Thrive

Jul 17, 2026, 8:46 AM EDT - 6 weeks ago

Use These ETFs as Health Stocks LLY, UNH, MRK Thrive

LLY UNH PPH VHT XLV

New Cholesterol Pill, Earnings Growth Boost Merck Shares

Jul 17, 2026, 8:40 AM EDT - 6 weeks ago

New Cholesterol Pill, Earnings Growth Boost Merck Shares

Why Healthcare Stocks Look Like a Haven in This Market

Jul 16, 2026, 5:07 PM EDT - 6 weeks ago

Why Healthcare Stocks Look Like a Haven in This Market

XLV

FDA signs off on Merck's cholesterol-lowering pill — the first oral treatment of its kind

Jul 16, 2026, 2:14 PM EDT - 6 weeks ago

FDA signs off on Merck's cholesterol-lowering pill — the first oral treatment of its kind

Merck's cholesterol pill gets US FDA approval

Jul 16, 2026, 6:49 AM EDT - 6 weeks ago

Merck's cholesterol pill gets US FDA approval

The FDA approved Lipfendra, a first-of-its kind pill from Merck that is designed to help lower cholesterol levels beyond what statins alone can achieve

Jul 16, 2026, 6:45 AM EDT - 6 weeks ago

The FDA approved Lipfendra, a first-of-its kind pill from Merck that is designed to help lower cholesterol levels beyond what statins alone can achieve

Merck Gets Approval for Powerful Cholesterol-Cutting Pill

Jul 16, 2026, 6:45 AM EDT - 6 weeks ago

Merck Gets Approval for Powerful Cholesterol-Cutting Pill

Merck's LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

Jul 16, 2026, 6:45 AM EDT - 6 weeks ago

Merck's LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026

Jul 15, 2026, 7:00 AM EDT - 6 weeks ago

Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Jul 10, 2026, 2:10 PM EDT - 7 weeks ago

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

Jul 1, 2026, 6:45 AM EDT - 2 months ago

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

US House committee opens investigation into Merck, AbbVie China drug trials

Jun 30, 2026, 6:02 AM EDT - 2 months ago

US House committee opens investigation into Merck, AbbVie China drug trials

ABBV

Merck & Company (MRK) Price Forecast: Can Momentum Drive New Highs?

Jun 29, 2026, 5:08 PM EDT - 2 months ago

Merck & Company (MRK) Price Forecast: Can Momentum Drive New Highs?

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

Jun 29, 2026, 6:45 AM EDT - 2 months ago

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 31 at 6:02 AM
$SLS $MRK $MRNA $ABBV $SLS is worth $50B to big pharma the instant Gps Phase 3 results are announced - any day now. • Why Did the VIALE-M Phase 3 Trial for AML First Remission Patients Fail? • Why DID ABBV have difficulty ENROLLING PATIENTS in the AML Maintenance Trial? Why are We SEEING MIRACULOUS Survival in the SLS Phase 3 AML Remission Maintenance Trial - when BAT for CONTROL Patients FAILED 2 Phase 3 AML Remission Trials?
0 · Reply
TradeThePool
TradeThePool Aug. 31 at 5:58 AM
Can $MRNA conquer cancer with AI and mRNA? First Phase 3 win for a personalized mRNA cancer vaccine. Intismeran plus $MRK Keytruda beat Keytruda alone on melanoma recurrence and spread. Up to 34 neoantigens per patient. Then a $2.6B zero-coupon convertible, upsized, with hedges to cap dilution. Argus to Buy, $180 target. XFG booster cleared by FDA and MHRA. COVID paid for the factory. Cancer is the bid. $MRNA $MRK #mRNA #Oncology #Biotech #CancerVaccine
0 · Reply
Duncan74
Duncan74 Aug. 31 at 2:46 AM
$BMY $JNJ $MRK $SLS If you think the auction is only about GPS maintenance, you are completely missing the SLS009 CDK9 hammer. The data room isn't just a clinical file cabinet. It’s a structural playground where SLS009 solves every single pipeline crisis Big Pharma is facing. JNJ’s Phase 3 bleximenib faces severe resistance because leukemia cells ramp up MCL-1 survival proteins. SLS009 is engineered specifically to downregulate and destroy MCL-1, giving JNJ the ultimate combination booster BMS’s current AML lines rely on venetoclax, but patients inevitably relapse. SLS009 has fully matured data proving it forces deep, clean remissions in patients who completely failed venetoclax. Merck needs SLS009 to clear out immune-suppressive myeloid barriers, priming the field for a massive Keytruda combination monopoly. Sellas owns a closed-loop rescue canopy. SLS009 forces the remission, and GPS locks the maintenance vault.
0 · Reply
Duncan74
Duncan74 Aug. 31 at 2:39 AM
$SLS $MRK $BMY $JNJ Let the three giants fight it out to see who writes the biggest upfront cash/stock check for a total oncology monopoly. This is a textbook bidding collision. 🔥Look at the corporate battle lines: 1. BMS: Must defensively protect its AML maintenance crown (Onureg) from JNJ's threatening Phase 3 cAMeLot-2 trials. Buying Sellas blocks JNJ and secures their monopoly. 2. JNJ: Slashed early R&D by 42%. Their lead asset bleximenib is stuck in a narrow 15% mutation niche. They must buy Sellas’s universal WT1 platform to capture the other 85% of AML patients. 3. Merck: Pipelines are dangerously top-heavy after Phase 1 starts tripled. Facing a massive patent cliff, they desperately need advanced Phase 3 anchors like GPS to pair with Keytruda and extend their oncology dominance. 🧬🚀
0 · Reply
TNNStockAnalysisNews
TNNStockAnalysisNews Aug. 31 at 1:36 AM
Stock Catalysts for September 2026: $KDK — Lockup Expiration: September 25 $XRPN — Shareholder Vote: September 30 $RKLB — Neutron Rocket Milestone Watch $BFRI — PDUFA Date: September 28 $MRK — PDUFA Date: September 21 https://truthsandnews.com/markets/stock-catalysts-september-2026-names-to-watch-now
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 30 at 9:12 PM
$SLS $MRK $MRNA $ABBV Gps Immunotherapy has proven Effective in preventing relapse and extending survival IN EVERY PREVIOUS TRIAL -- Including 2 Phase 2 Trials for AML Remission Maintenance. *Phase 3 Trial Results Imminent. Oral Aza -Onureg is the SOC for AML Patients in First Remission - achieved a MOS of 24.7 Months. $ABBV Conducted the VIALE-M PH3 trial Combining Oral Az w Venetoclax - it FAILED. GPS MOS in this Same First Remission Setting Achieved PH2 MOS >67.6 Months. SOC: 24.7 --- GPs: > 67.6 Again Note the Key Gps Specific Immune Response. Onureg Ph3 and GPS P2 Patients were not Eligible for Transplant. 6.7% of the Onureg CR1 Patients Subsequently rec'd transplant.
0 · Reply
Mike22332233
Mike22332233 Aug. 30 at 3:29 PM
$SLS 👉 HERE IS WHAT YOU MUST DO RIGHT NOW WITH SLS ... With proper DD, the outcome here has been clear since the last couple of weeks in December ... The easiest stock to hold is one in which, after doing all your DD, you DO NOT HAVE TO DO ANYMORE THINKING .... just sit back, hold all your shares, and wait !!! I STAND BY ALL MY FOLLOWING RESEARCH ... My current calculation of HR is: 0.25-0.30 * Best asymmetrical play in my 43 yrs investing * At 80th -- 46 GPS/0 BAT Live * GROUNDBREAKING HR * New SoC in AML * GPS in 20 other cancers next * SLS009 only safe CDK9 inhibitor * Minimum BO Offer = $160 * Final Bidding War BO = $222 * Buyer will be $MRK or RHHBY Many don't understand all the positives for the LONGER it takes to get to 80th ... * Patients live longer * HR Value gets lower * BO Valuation gets higher * More will get LT Cap Gains LIKE IF U AGREE ... FOLLOW me 👉 @Mike22332233 to get all SLS info
0 · Reply
NewbieJR
NewbieJR Aug. 30 at 1:16 PM
$MRK
0 · Reply
NewbieJR
NewbieJR Aug. 30 at 9:43 AM
$MRK
0 · Reply
NewbieJR
NewbieJR Aug. 30 at 9:38 AM
$MRK
0 · Reply
NewbieJR
NewbieJR Aug. 30 at 8:28 AM
$MRK .....citadel crooks wont have any edge if retails stop using scam brokers like Robinhood , trading 212... these scamners loan out retail investors shares to their crime partner citadel crooks without any borrowing cost..as soon as retail buy with them.. doesnt matter you using margin or non margin account..
0 · Reply
Juhanialainen
Juhanialainen Aug. 30 at 7:30 AM
$SLS Looks like the cancer vaccine space is going to get similar hype on us like the quantum sector had few years back. $MRNA $MRK $JNJ
0 · Reply
None_
None_ Aug. 29 at 6:34 PM
$MRK https://www.statnews.com/2022/05/10/it-took-years-but-the-failure-and-futility-of-northwest-bios-brain-cancer-vaccine-is-now-in-the-open/
0 · Reply
Duncan74
Duncan74 Aug. 29 at 4:49 PM
$SLS $MRK $JNJ Big Pharma is in a massive pipeline crisis, and they desperately need Sellas. Inside the VDR under strict NDAs, the industry is split in two: 🏢 CAMP A: THE SCALERS (Merck/AZ) Pipelines are top-heavy and near-term revenue engines are stalling. They NEED advanced Phase 3 oncology anchors right now to protect market share. 🧬 CAMP B: THE STREAMLINERS (J&J/Roche) Internal discovery engines are completely OFF after slashing early R&D. They MUST buy external, de-risked assets because they outsourced innovation. Why is management holding through this strict SEC Quiet Period? To completely eliminate the risk-discount before the 80th REGAL event unblinds. Forget complicated CVR milestone nonsense—we want a straight, heavy Upfront Cash + Liquid Stock buyout for immediate monetization. Let them fight it out to see who writes the biggest upfront check for a total monopoly. SELLAS is not desperate. The BP facing patent cliff is.
1 · Reply
vermigli
vermigli Aug. 29 at 3:46 PM
I love dividend growth stocks because its like I get a raise every year just for holding. TTM Growth Rates (according to Seeking Alpha): $SPG 5.39% $MRK 5.04% $PEP 4.74% $CVX 4.49% $JNJ 4.38%
1 · Reply
ILuvbiotech
ILuvbiotech Aug. 29 at 3:28 PM
$MRK 's partnership with Moderna has brought huge attention to personalised cancer vaccines. But there's another approach investors should probably have on their radar: $NWBO and DCVax-L. It's not mRNA — it's a personalised dendritic-cell therapy for GBM that has already completed Phase 3 and is now awaiting a UK regulatory decision. Not saying they're the same thing, but the comparison is interesting.
2 · Reply
tr3ndo
tr3ndo Aug. 29 at 12:16 PM
$MRK a seller zone formed, a local maximum was confirmed, and a downward correction is developing on the daily chart around $149. Price is reacting from the recent highs. AI Detective currently assigns a 47% probability to a local minimum being confirmed next. Watching the next move closely.
0 · Reply
NewbieJR
NewbieJR Aug. 29 at 9:49 AM
$MRK ...leopole should be fine if wasnt leveraged.. citadel crooks done the harm that young boy....citadel crooks wont have any edge if retails stop using scam brokers like Robinhood , trading 212... these scamners loan out retail investors shares to their crime partner citadel crooks without any borrowing cost..as soon as retail buy with them.. doesnt matter you using margin or non margin account..
0 · Reply
LagunaZ06
LagunaZ06 Aug. 28 at 11:14 PM
$MRK today was a gift if the market bounce next week after ingesting Warsh’s slop salad speech. Loaded $150 Novemebr Calls.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 28 at 8:21 PM
$SLS $MRK $MRNA YOU NEVER HAVE A PROBLEM ENROLLING A TRIAL WHERE PATIENTS ARE DOING WELL... Just checking -- Does Everyone KNOW AZA+VEN -BAT for the SLS Phase 3 Control Arm Patients FAILED 3 large Phase 3 Trials. - BAT for the SLS P3 Control ARM Failed 3 Large Phase 3 Trials Conducted by $ABBV While we are seeing Miraculous ALL POOLED Survival - BAT - FAILED the VIALE-M CR1 First Remission AML Maintenance Trial VIALE-T Post Transplant AML Maintenance Trial ABBV stated poor accrual/enrollment in the CR1 Maintenance trial as a reason for the FAILURE --- YOU NEVE HAVE A PROBLEM ENROLLING A TRIAL WHERE PATIENTS ARE DOING WELL...
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 28 at 7:59 PM
$SLS $MRK $MRNA Weak Volume for the price decline.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 28 at 7:19 PM
$SLS $MRK $MRNA $ABBV Investment Opportunity of a Lifetime for Anyone Investing in SLS ahead of the Imminent Phase 3 Trial Results. • 15X • 20X ROI any day now.
0 · Reply